Medium Evidence Level Drugs
Candidates with preliminary evidence requiring further validation
Evidence Standards
| Level | Definition | Clinical Significance |
|---|---|---|
| L3 | Observational studies / Large case series | Preliminary evidence, needs RCT |
| L4 | Preclinical / Mechanistic / Case reports | Mechanism reasonable, lacks clinical validation |
Drug List
L3 Level (1 drugs)
| Drug Name | Indications | Link |
|---|---|---|
| Pemetrexed | 51 | View Report |
L4 Level (3 drugs)
| Drug Name | Indications | Link |
|---|---|---|
| Eptifibatide | 51 | View Report |
| Febuxostat | 50 | View Report |
| Simoctocog Alfa | 50 | View Report |
Criteria for L3-L4 Classification
L3 Requirements
- Cohort or case-control study
- OR large case series (≥50 patients)
- Published results with quantitative outcomes
L4 Requirements
- In vitro or animal studies showing efficacy
- OR mechanistic rationale with supporting data
- OR case reports (< 10 patients)